All In Biotech

Drug Trial Radar · NCT02452866

Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis

Last checked: Nov 20, 2026Latest source record: Apr 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

325

Actual

Start

Jun 2015

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Symbiomix TherapeuticsIndustry
Sponsor type
Industry
First posted
May 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multi-center, prospective, open-label study to evaluate the safety of SYM-1219 granules containing 2 grams of secnidazole in women and postmenarchal adolescent girls with bacterial vaginosis.

Conditions

  • Bacterial Vaginosis

Interventions

  • SYM-1219Drug

    Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers of Participants With Treatment Emergent Adverse Events and Laboratory AbnormalitiesTime frame: 30days

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    La Mesa, California

  • Site not named

    San Diego, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Groton, Connecticut

  • Site not named

    Clearwater, Florida

  • Site not named

    Leesburg, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Wellington, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Roswell, Georgia

  • Site not named

    Shawnee Mission, Kansas

  • Site not named

    Baltimore, Maryland

  • Site not named

    Fall River, Massachusetts

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Saginaw, Michigan

  • Site not named

    Plainsboro, New Jersey

  • Site not named

    New Bern, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Columbus, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Myrtle Beach, South Carolina

  • Site not named

    Jackson, Tennessee

  • Site not named

    Corpus Christi, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Norfolk, Virginia

  • Site not named

    Virginia Beach, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.